Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 8Terminated 4Withdrawn 1Unknown 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Neoplasm Metastasis 2Neoplasms 1Hypersensitivity 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × ZD4054 × Clear all
NCT01119118 2019-11-21

ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer

University of Wisconsin, Madison

Phase 2 Terminated
6 enrolled 6 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT01000948 2014-01-08

DAPROCA-1

Aarhus University Hospital

Phase 2 Terminated
24 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00626548 2012-09-03

ENTHUSE M0

AstraZeneca

Phase 3 Terminated
2,577 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

NCT00929162 2012-08-07

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

AstraZeneca

Phase 2 Terminated
120 enrolled 8 charts

Hypersensitivity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡